Analysts Issue Forecasts for FBIO FY2025 Earnings

Fortress Biotech, Inc. (NASDAQ:FBIO) – Equities researchers at HC Wainwright issued their FY2025 earnings estimates for Fortress Biotech in a note issued to investors on Tuesday, January 13th. HC Wainwright analyst J. Pantginis anticipates that the biopharmaceutical company will post earnings per share of ($0.20) for the year. The consensus estimate for Fortress Biotech’s current full-year earnings is ($3.28) per share. HC Wainwright also issued estimates for Fortress Biotech’s Q4 2025 earnings at $0.42 EPS, FY2026 earnings at $0.62 EPS and FY2027 earnings at $1.51 EPS.

Fortress Biotech (NASDAQ:FBIO) last posted its earnings results on Friday, November 14th. The biopharmaceutical company reported $0.11 EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.54. Fortress Biotech had a net margin of 6.40% and a negative return on equity of 69.39%. The firm had revenue of $17.63 million for the quarter, compared to the consensus estimate of $21.02 million.

FBIO has been the topic of a number of other research reports. Weiss Ratings reiterated a “sell (d+)” rating on shares of Fortress Biotech in a research report on Monday, December 29th. Wall Street Zen raised Fortress Biotech from a “hold” rating to a “buy” rating in a research report on Sunday, November 23rd. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $16.50.

Fortress Biotech Price Performance

Shares of FBIO opened at $3.48 on Thursday. The company has a debt-to-equity ratio of 0.73, a current ratio of 2.19 and a quick ratio of 1.97. Fortress Biotech has a 1-year low of $1.33 and a 1-year high of $4.53. The stock has a market cap of $108.02 million, a PE ratio of -19.33 and a beta of 1.42. The firm has a fifty day moving average price of $3.21 and a 200 day moving average price of $2.78.

Hedge Funds Weigh In On Fortress Biotech

Several institutional investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE grew its holdings in Fortress Biotech by 923.3% during the third quarter. Bank of America Corp DE now owns 7,122 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 6,426 shares during the period. Abacus Planning Group Inc. purchased a new stake in shares of Fortress Biotech during the 3rd quarter worth $54,000. Scientech Research LLC acquired a new position in shares of Fortress Biotech during the 3rd quarter worth $67,000. XTX Topco Ltd purchased a new position in shares of Fortress Biotech in the 2nd quarter valued at about $42,000. Finally, Osaic Holdings Inc. increased its holdings in shares of Fortress Biotech by 18.4% in the 2nd quarter. Osaic Holdings Inc. now owns 32,379 shares of the biopharmaceutical company’s stock valued at $60,000 after purchasing an additional 5,034 shares in the last quarter. Institutional investors and hedge funds own 96.51% of the company’s stock.

Fortress Biotech Company Profile

Fortress Biotech, Inc is a clinical‐stage biopharmaceutical company focused on acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Headquartered in New York, the company operates through a network of majority‐owned subsidiaries that target areas of high unmet medical need, including oncology, rare diseases and dermatology. Fortress Biotech’s business model emphasizes in‐licensing or acquiring promising drug candidates and coordinating their development through specialized affiliate companies, allowing for flexible capital allocation and focused management of individual programs.

Through its portfolio of subsidiaries, Fortress Biotech advances a diversified pipeline spanning small molecules, biologics and cell therapies.